T1	Participants 123 160	women with early-stage breast cancer.
T2	Participants 450 476	early-stage breast cancer.
T3	Participants 536 648	20 women with early-stage breast cancer receiving four courses of cyclophosphamide and doxorubicin chemotherapy.
